Abstract:Background: Lung cancer remains the leading cause of cancer-related death and despite advances in low-dose CT screening, most lung cancer patients still present with advanced disease. The development of assays that are sensitive, specific, economical, and non-invasive may lead to the development of further effective screening strategies. Non-invasive liquid biopsy by detection in plasma of circulating tumor DNA (ctDNA) carrying somatic lung cancer mutations is now routinely used for identifying targeted therapy options in advanced non-small cell lung cancer (NSCLC) patients. Recent adaptation of bacterial CRISPR-Cas13a systems with promiscuous ribonuclease activity into reporter assays for the sensitive and economical detection of specific nucleic acid sequences makes an attractive system for ctDNA detection without needing more costly next-generation sequencing (NGS) techniques. Methods: We adapted the CRISPR-Cas13a system used in the SHERLOCK detection assay for the detection of common driver mutations (KRAS G12C/V, EGFR Exon 19 deletion, and EGFR L858R) in NSCLC and tested the assay on a retrospective cohort of 52 NSCLC patients with known mutations (based on tissue NGS) and with plasma obtained prior to or at the time of any surgical resection and a prospective cohort of 71 patients who underwent lung resection with plasma collected at the time of surgical resection. Results: We designed several CRISPR guide RNAs targeting common EGFR and KRAS oncogenic mutations in NSCLC and were able to generate sensitive CRISPR-Cas13a detection assays against KRAS G12C and G12V, EGFR L858R, and EGFR E746_A750 exon 19 deletion mutations that could identify allele fractions below 1% in reference standards. We then tested plasma of a 52 patient (33 advanced stage IIIB and IV, 19 resectable stage I-IIIA) retrospective cohort with known KRAS and EGFR mutations and matching non-cancer controls using the CRISPR-Cas13a assay as well as with NGS panels (ArcherDx). Using NGS, we were able to confirm ctDNA in 15 samples which we were also able to detect using the CRISPR-Cas13a assay with similar allele frequencies. The CRISPR-Cas13a assay was able to identify ctDNA in 42 out of the 52 retrospective NSCLC samples including 13 out of 19 samples from resectable-stage patients, although the detection rate decreased with earlier stage I and II patients who have a much lower ctDNA level in plasma. We then prospectively collected a cohort of 71 subjects who underwent surgical resection with 38 subjects with lung adenocarcinoma (mostly stage I and II), 11 subjects with benign nodules, and 22 subjects with a different histology malignancy. Our CRISPR-Cas13a assay was able to detect 9 out of 38 lung adenocarcinomas with no false positives in subjects with benign nodules. Conclusion: We adapted a CRISPR-Cas13a assay for the detection of ctDNA in NSCLC and evaluated this assay on plasma from NSCLC subjects. Citation Format: Edwin H. Yau, Bojidar Kandar, Catrina Ting, Sai Yendamuri, Mary Reid. Detection of circulating tumor DNA using CRISPR-Cas13a in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3404.

ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies

dPCR application in liquid biopsies: divide and conquer

Abstract 3380: Use of liquid biopsy for detection of pathogenic variants in cell-free tumor DNA from patients with precursor lesions and colorectal cancer

Abstract A022: Novel technology affords real-time PCR the sensitivity required for minimal residual disease monitoring

Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay

Abstract 3404: Detection of circulating tumor DNA using CRISPR-Cas13a in non-small cell lung cancer

Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge

CRISPincette, and detection of low frequency cancer mutations in ctDNA.

Discrimination of the V600E Mutation in BRAF by Rolling Circle Amplification and Förster Resonance Energy Transfer

Real-time Digital Polymerase Chain Reaction (PCR) As a Novel Technology Improves Limit of Detection for Rare Allele Assays.

The fluorescence amplification strategy based on 3D DNA walker and CRISPR/Cas12a for the rapid detection of BRAF V600E

Abstract 1470: Advancing cancer research: A novel PanCancer digital PCR tool for simultaneous detection of multiple hallmark mutations in BRAF and EGFR

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research.

Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study

Implementation of a Pilot Study to Analyze Circulating Tumor DNA in Early-Stage Lung Cancer

"Sample-to-answer" detection of rare ctDNA mutation from 2-mL plasma with a fully integrated DNA extraction and digital droplet PCR microdevice for liquid biopsy.

Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients

CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma